Skip to search formSkip to main contentSkip to account menu

ACT-333679

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
2019
2019
Cross-species comparison of the metabolism and excretion of selexipag
Abstract 1. The metabolism of the prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269… 
Review
2018
Review
2018
A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
BACKGROUND This review focuses on the treatment of pulmonary arterial hypertension (PAH) with selexipag and compares its drug… 
Review
2017
Review
2017
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review
ABSTRACT Introduction: Pulmonary hypertension is defined by a mean pulmonary artery pressure ≥25 mm Hg at rest. Management of… 
Review
2017
Review
2017
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
ABSTRACT Introduction: Selexipag is the first oral, non-prostanoid, selective prostacyclin receptor (IP receptor) agonist… 
2015
2015
Authors’ Reply to Srinivas: “Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag”
We thank Dr. Srinivas for his interest in our study and for the opportunity to respond to the letter [1]. While we agree with… 
2013
2013
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
2013
2013
PP192—Pharmacokinetics of Selexipag in Subjects with Severe Renal Impairment Compared with Healthy Subjects
2013
2013
PP195—Voriconazole Adjustment from Twice to Three Times Daily in Cystic Fibrosis Lung Transplant Patients
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)